1. Home
  2. MNSB vs MDXH Comparison

MNSB vs MDXH Comparison

Compare MNSB & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MainStreet Bancshares Inc.

MNSB

MainStreet Bancshares Inc.

HOLD

Current Price

$24.81

Market Cap

172.3M

Sector

Finance

ML Signal

HOLD

Logo MDxHealth SA

MDXH

MDxHealth SA

HOLD

Current Price

$2.01

Market Cap

149.0M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
MNSB
MDXH
Founded
2003
2003
Country
United States
Belgium
Employees
171
N/A
Industry
Major Banks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
172.3M
149.0M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
MNSB
MDXH
Price
$24.81
$2.01
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$7.67
AVG Volume (30 Days)
54.8K
186.7K
Earning Date
04-20-2026
05-14-2026
Dividend Yield
1.62%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$1.50
$30.78
Revenue Next Year
$3.77
$18.31
P/E Ratio
$12.64
N/A
Revenue Growth
N/A
N/A
52 Week Low
$17.86
$1.67
52 Week High
$25.17
$5.33

Technical Indicators

Market Signals
Indicator
MNSB
MDXH
Relative Strength Index (RSI) 65.79 30.28
Support Level $20.84 $1.96
Resistance Level $25.14 $2.37
Average True Range (ATR) 0.71 0.14
MACD 0.08 0.02
Stochastic Oscillator 66.67 0.00

Price Performance

Historical Comparison
MNSB
MDXH

About MNSB MainStreet Bancshares Inc.

MainStreet Bancshares Inc is a bank holding company. It is focused on serving the borrowing, cash management and depository needs of small to medium-sized businesses, and professional practices and retail customers. The bank's products and services include business and consumer checking, premium interest-bearing checking, business account analysis, savings, certificates of deposit and other depository services, as well as a broad array of commercial, real estate and consumer loans.

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

Share on Social Networks: